

Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2005¹

Reporting Area	Total Cases	Therapy ≤1 Year Indicated ²			Therapy >1 Year Indicated ³		All Drug Therapy	
		No. ⁴	COT ≤1 Year(%)	COT(%)	No. ⁴	COT(%)	No. ⁴	COT(%)
United States	14,065	12342	(82.7)	(91.9)	346	(82.7)	12688	(91.7)
Alabama	216	194	(89.7)	(94.8)	3	(33.3)	197	(93.9)
Alaska	59	57	(93.0)	(96.5)	1	(100.0)	58	(96.6)
Arizona	281	245	(83.3)	(87.3)	3	(100.0)	248	(87.5)
Arkansas	117	103	--	--	2	--	105	--
California	2,900	2544	(80.7)	(91.9)	71	(80.3)	2615	(91.6)
Colorado	101	85	(96.5)	(97.6)	4	(100.0)	89	(97.8)
Connecticut	95	87	(82.8)	(97.7)	1	(100.0)	88	(97.7)
Delaware	27	24	(87.5)	(100.0)	0	...	24	(100.0)
District of Columbia	55	49	(87.8)	(93.9)	3	(33.3)	52	(90.4)
Florida	1,093	967	(88.6)	(94.6)	21	(95.2)	988	(94.6)
Georgia	505	449	(82.0)	(93.1)	11	(72.7)	460	(92.6)
Hawaii	112	95	(74.7)	(88.4)	0	...	95	(88.4)
Idaho	23	21	(76.2)	(85.7)	0	...	21	(85.7)
Illinois	589	524	(80.0)	(91.4)	5	(80.0)	529	(91.3)
Indiana	146	133	(91.0)	(95.5)	1	(100.0)	134	(95.5)
Iowa	55	52	(84.6)	(94.2)	0	...	52	(94.2)
Kansas	60	57	(86.0)	(91.2)	0	...	57	(91.2)
Kentucky	124	104	(87.5)	(93.3)	3	(100.0)	107	(93.5)
Louisiana	257	218	--	--	3	--	221	--
Maine	17	16	(75.0)	(75.0)	1	(100.0)	17	(76.5)
Maryland	283	249	(88.4)	(94.8)	8	(100.0)	257	(94.9)
Massachusetts	266	235	(78.3)	(89.8)	12	(75.0)	247	(89.1)
Michigan	245	201	(80.1)	(91.5)	8	(75.0)	209	(90.9)
Minnesota	199	183	(92.9)	(97.8)	7	(100.0)	190	(97.9)
Mississippi	103	84	(84.5)	(95.2)	2	(100.0)	86	(95.3)
Missouri	108	91	(85.7)	(96.7)	3	(66.7)	94	(95.7)
Montana	10	8	(87.5)	(100.0)	0	...	8	(100.0)
Nebraska	35	29	(75.9)	(82.8)	3	(100.0)	32	(84.4)
Nevada	112	106	--	--	1	--	107	--
New Hampshire	4	4	(75.0)	(100.0)	0	...	4	(100.0)
New Jersey	482	420	(85.7)	(93.3)	15	(93.3)	435	(93.3)
New Mexico	39	26	(80.8)	(100.0)	2	(100.0)	28	(100.0)
New York State ⁵	300	266	(87.2)	(97.4)	9	(77.8)	275	(96.7)
New York City	984	845	(81.9)	(90.5)	44	(77.3)	889	(89.9)
North Carolina	329	290	(86.2)	(96.6)	8	(100.0)	298	(96.6)
North Dakota	6	6	(50.0)	(83.3)	0	...	6	(83.3)
Ohio	260	231	(87.0)	(94.8)	7	(85.7)	238	(94.5)
Oklahoma	144	118	(84.7)	(97.5)	3	(66.7)	121	(96.7)
Oregon	103	95	(93.7)	(96.8)	1	(100.0)	96	(96.9)
Pennsylvania	320	270	--	--	6	--	276	--
Rhode Island	47	41	(82.9)	(95.1)	1	(0.0)	42	(92.9)
South Carolina	261	232	(87.1)	(96.1)	7	(71.4)	239	(95.4)
South Dakota	16	13	(53.8)	(100.0)	0	...	13	(100.0)
Tennessee	299	267	(88.8)	(96.6)	7	(85.7)	274	(96.4)
Texas	1,526	1334	(80.6)	(89.7)	42	(83.3)	1376	(89.5)
Utah	29	26	(96.2)	(96.2)	2	(100.0)	28	(96.4)
Vermont	8	7	(100.0)	(100.0)	0	...	7	(100.0)
Virginia	355	321	(81.9)	(90.7)	7	(100.0)	328	(90.9)
Washington	254	226	(83.2)	(92.0)	6	(83.3)	232	(91.8)
West Virginia	28	24	(58.3)	(87.5)	0	...	24	(87.5)
Wisconsin	78	70	(84.3)	(90.0)	2	(100.0)	72	(90.3)
Wyoming	0	0	--	--	0	...	0	--
American Samoa ⁶	5	5	--	--	0	--	5	--
Fed. States of Micronesia ⁶	74	72	--	--	1	--	73	--
Guam ⁶	64	59	(79.7)	(88.1)	1	(0.0)	60	(86.7)
Marshall Islands ⁶	66	63	--	--	0	--	63	--
N. Mariana Islands ⁶	56	54	--	--	1	--	55	--
Puerto Rico ⁶	113	86	(87.2)	(94.2)	1	(100.0)	87	(94.3)
Republic of Palau ⁶	10	10	(100.0)	(100.0)	0	...	10	(100.0)
U.S. Virgin Islands ⁶	0	0	--	--	0	--	0	--

¹Most recent year for which data are available.

²Initial isolate susceptible to rifampin (n=9,212) or susceptibility unknown (n=223); culture negative (n=2,346); culture status unknown (n=561); age unknown (n=0).

³Initial isolate rifampin resistant, or pediatric patients (aged <15) with meningeal, bone, joint, or military disease.

⁴Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information reported for ≥90% of cases.

⁵Excludes New York City.

⁶Not included in U.S. totals.

Note: Ellipses indicate data not available. See Technical Notes for description of Completion of Therapy calculation (page 9).